Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
MaxCyte ( (MXCT) ) has provided an announcement.
MaxCyte, Inc. announced its preliminary unaudited financial results for the fourth quarter and full year 2024, showing core revenue growth of 8 to 9% compared to the previous year and an increase in cash reserves to approximately $190 million. The company reported an improved operating environment in the cell therapy industry and highlighted achievements such as increasing SPL customers and supporting the FDA approval of a non-viral gene-edited cell therapy product. These developments position MaxCyte for continued growth and operational efficiency as they move into 2025.
More about MaxCyte
MaxCyte, Inc. is a leader in the cell engineering industry, specializing in platform technologies that enhance the discovery, development, and commercialization of next-generation cell therapeutics. The company operates with a strong focus on the high-growth cell therapy market, utilizing its proprietary ExPERT™ platform based on Flow Electroporation® technology. MaxCyte offers a range of instruments, processing assemblies, and software protocols designed to support the cell therapy sector from discovery through commercialization.
YTD Price Performance: 8.33%
Average Trading Volume: 49,774
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £380.2M
For an in-depth examination of MXCT stock, go to TipRanks’ Stock Analysis page.
